NYSE | TSX: ACB
EDMONTON, AB, May 20, 2021 /PRNewswire/ -- Aurora Germany
GmbH, a subsidiary of Aurora Cannabis Inc. (the "Company" or
"Aurora") (NYSE: ACB) (TSX: ACB), the Canadian company
defining the future of cannabinoids worldwide, and Grow Group PLC
("Grow"), a biopharmaceutical company focused on improving access
to cannabis-based medicines in the United
Kingdom ("UK"), today announced the extension of their
long-standing strategic relationship by signing a two-year market
access services agreement for the UK. Aurora was one of the first
companies to enter into a strategic relationship with Grow in
August 2019 and since then, both
companies have become leaders in the rapidly growing medical
cannabis market in the UK.
"We are delighted to extend our existing strategic relationship
with Grow," stated Miguel Martin,
Chief Executive Officer of Aurora Cannabis. "We have worked
successfully with Grow and their joint venture partner, IPS, since
entering the UK market. Renewing this agreement will help to
broaden access for patients by leveraging Grow's work educating
physicians and creating awareness of medical cannabis options.
Aurora is committed to providing access to legally produced
high-quality pharmaceutical-grade medical cannabis to address the
needs of the growing European medical cannabis market, made
possible with our EU GMP facility, Aurora Nordic."
"Everything we do is with the patient in mind. Addressing
patients' needs and broadening access to medical cannabis in the UK
is at the heart of Grow's strategy," said Pierre van Weperen,
Managing Director of Grow Group PLC, UK & Ireland. "Quality of products, broad range of
offerings and a strong supply chain is critical to serving the UK's
fast-growing patient population. Partnering with companies like
Aurora will continue to enable us to offer a portfolio of
high-quality flowers and extracts to doctors and the patients who
will benefit from them. Every day, these products make a difference
for patients and we look forward to advancing market access
together with Aurora."
About Aurora
Aurora is a global leader in the cannabis
industry serving both the medical and consumer markets.
Headquartered in Edmonton, Alberta,
Canada, Aurora is a pioneer in global cannabis dedicated to
helping people improve their lives. The Company's brand portfolio
includes Aurora, Aurora Drift, San Rafael '71, Daily Special,
AltaVie, MedReleaf, CanniMed, Pedanios, Whistler, and Reliva CBD.
Providing customers with innovative, high-quality cannabis
products, Aurora's brands continue to break through as industry
leaders in the medical, performance, wellness and recreational
markets wherever they are launched. For more information, please
visit our website at www.auroramj.com.
Aurora's common shares trade on the TSX and NYSE under the
symbol "ACB", and is a constituent of the S&P/TSX Composite
Index.
About Grow Group PLC
Grow Group PLC exists to unlock
the medical potential of cannabis for those who need it through
three business units: Grow Pharma, Grow Trading and Grow Biotech.
Grow Pharma works with the producers of the best cannabis-based
medicines and helps them introduce their products in new markets
like the UK and Ireland, creating
long-term value for them and offering solutions for patients. The
Grow Pharma team also focuses on supporting clinics and individual
healthcare professionals and through our partnership with IPS
Specials Pharma we work with the best importer, distributor, and
pharmacy in the country to deliver the medication to patients.
Ultimately, all Grow Group activities are aimed at improving
patient access to cannabis medicines. Learn more about us at
www.growgroupplc.com and follow us on LinkedIn
www.linkedin.com/company/grow-grow-plc.
Photo -
https://mma.prnewswire.com/media/1514142/Aurora_Cannabis_Inc__Aurora_Cannabis_and_Grow_Group_PLC_Renew_Ma.jpg
For Media: Michelle Lefler, VP, Communications & PR,
media@auroramj.com; Yvonne Moeller,
Director Communications Europe, press@auroramedicine.com; For
Investors: ICR, Inc., Investor Relations, aurora@icrinc.com